Effect of exposure to non-esterified fatty acid on progressive deterioration of insulin secretion in patients with Type2 diabetes: A long-term follow-up study

Diabetic Medicine

Volumn 29, Issue 8, 2012, Pages 980-985

  Morita, S ^a   Shimajiri, Y ^a   Sakagashira, S ^a   Furuta, M ^a   Sanke, T ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Insulin secretion; Non esterified fatty acid; Type2 diabetes

Indexed keywords

C PEPTIDE; FATTY ACID; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; TOLBUTAMIDE;

ADULT; ARTICLE; BODY MASS; CALORIC INTAKE; CALORIC RESTRICTION; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE INCREASE; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN RELEASE; INSULIN TREATMENT; JAPANESE; LIFESTYLE MODIFICATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT CARE; PROTEIN BLOOD LEVEL; WEIGHT REDUCTION;

ADULT; BODY MASS INDEX; C-PEPTIDE; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; FASTING; FATTY ACIDS, NONESTERIFIED; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; TRIGLYCERIDES;

EID: 84864015694     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2011.03566.x     Document Type: Article

References (23)

1. Kahn SE. The relative contributions of insulin resistance and β-cell dysfunction to the pathophysiology of Type2 diabetes. Diabetologia 2003; 46: 3-19.
2. Kahn SE, Zraika S, Utzschneider KM, Hull RL. The β-cell lesion in type2 diabetes: there has to be a primary functional abnormality. Diabetologia 2009; 52: 1003-1012.
3. Cho JH, Kim JW, Shin JA, Shin J, Yoon KH. Beta-cell mass in people with type2 diabetes. J Diabetes Invest 2011; 2: 6-17.
4. Rhodes CJ. Type2 diabetes-a matter of β-cell life and death? Science 2005; 307: 380-384.
5. Marchetti P, Lupi R, Del Guerra S, Bugliani M, D'aleo V, Occhipinti M et al. Goals of treatment for type2 diabetes: β-cell preservation for glycemic control. Diabetes Care 2009; 32: S178-S183.
6. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007; 28: 187-218.
7. van Raalte DH, van der Zijl NJ, Diamant M. Pancreatic steatosis in humans: cause or marker of lipotoxicity? Curr Opin Clin Nutr Metab Care 2010; 13: 478-485.
8. Prentki M, Nolan CJ. Islet β-cell failure in type2 diabetes. J Clin Invest 2006; 116: 1802-1812.
9. Lee Y, Hirose H, Ohneda M, Johnson JH, McGarry JD, Unger RH. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-β-cell relationships. Proc Natl Acad Sci U S A 1994; 91: 10878-10882.
10. Lupi R, Dotta F, Marselli L, Del Guerra S, Masini M, Santangelo C et al. Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that β-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. Diabetes 2002; 51: 1437-1442.
11. Boden G, Lebed B, Schatz M, Homko C, Lemieux S. Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes 2001; 50: 1612-1617.
12. Kashyap S, Belfort R, Gastaldelli A, Pratipanawatr T, Berria R, Pratipanawatr W et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type2 diabetes. Diabetes 2003; 52: 2461-2474.
13. Charles MA, Eschwege E, Thibult N, Claude JR, Warnet JM, Rosselin GE et al. The role of non-esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: results of the Paris Prospective Study. Diabetologia 1997; 40: 1101-1106.
14. Paolisso G, Tataranni PA, Foley JE, Bogardus C, Howard BV, Ravussin E. A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia 1995; 38: 1213-1217.
15. Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y, Kobayashi M et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract 2002; 55: 65-85.
16. Yoshiike N, Zaman M, Matumaru Y, Yamaguchi M. Descriptive epidemiology of body mass index in Japanese adults in a representative sample from the National Nutrition Survey 1990-1994. Int J Obes 1998; 22: 684-687.
17. Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. J Diabetes Invest 2010; 1: 212-228.
18. Morita S, Sakagashira S, Ueyama M, Shimajiri Y, Furuta M, Sanke T. Progressive deterioration of insulin secretion in Japanese type2 diabetic patients in comparison with those who carry the S20G mutation of the islet amyloid polypeptide gene: a long-term follow-up study. J Diabetes Invest 2011; 2: 287-292.
19. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type2 diabetes in obese patients. Diabetes Care 2004; 27: 155-161.
20. Kelley DE, Kuller LH, McKolanis TM, Harper P, Mancino J, Kalhan S. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type2 diabetes. Diabetes Care 2004; 27: 33-40.
21. Shimabukuro M, Zhou YT, Levi M, Unger RH. Fatty acid-induced β-cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci U S A 1998; 95: 2498-2502.
22. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 1995; 44: 863-870.
23. Prentki M, Joly E, El-Assaad W, Roduit R. Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity: role in β-cell adaptation and failure in the etiology of diabetes. Diabetes 2002; 51: S405-S413.